Skip to main
CLPT

CLPT Stock Forecast & Price Target

CLPT Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ClearPoint Neuro Inc is positioned for a robust growth trajectory, with the company achieving 17% topline growth in 2023 and demonstrating a significant reduction in cash burn, indicating improved financial efficiency. The expansion of its partnership base and introduction of higher value service offerings in the Biologics space are projected to drive at least 20% revenue growth in 2024. Additionally, the company is gaining momentum through key product approvals, record system installations, and supportive clinical publications, which enhances its market prospects and overall financial stability.

Bears say

ClearPoint Neuro Inc. has demonstrated a significant reduction in cash burn throughout 2023, decreasing from $5.8 million in the first quarter to $1.2 million in the fourth quarter, which could suggest a positive trend in managing operational expenses. However, despite this improvement in cash management, the company's reliance on minimizing cash burn may indicate underlying challenges in revenue generation and overall demand for its products. Furthermore, the expectation to continue this trend in 2024 raises concerns about the company's strategic growth potential and its ability to invest effectively in research and development or market expansion.

CLPT has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearpoint Neuro Inc (CLPT) Forecast

Analysts have given CLPT a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLPT has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearpoint Neuro Inc (CLPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.